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Abstract 
Carnitine octanoyltransferase (COT) produces 
three different transcripts in rat through cis- and 
trans-splicing reactions, which can lead to the 
synthesis of two proteins. The occurrence of the 
three COT transcripts in rat has been found in all 
tissues examined and does not depend on sex, fat 
feeding, peroxisome proliferators or hyperinsulin- 
aemia. Rat COT exon 2 contains a putative exonic 
splicing enhancer (ESE) sequence. Mutation of 
this ESE (GAAGAAG) to AAAAAAA decreased 
trans-splicing in vitro, from which it is deduced 
that this ESE sequence is partly responsible for 
Key words: etornoxir, exonic splicing enhancers, rnalonyl-CoA, 
trans-splicing. 
Abbreviations used: COT, camitine octanoyltransferase; CPT, 
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the formation of the three transcripts. The protein 
encoded by cis-spliced mRNA of rat COT is 
inhibited by malonyl-CoA and etomoxir. cDNA 
species encoding full-length wild-type COT and 
one double mutant COT were expressed in 
Saccharomyces cerevisiae. The recombinant 
enzymes showed full activity towards both sub- 
strates, carnitine and decanoyl-CoA. The activity 
of the doubly mutated H131A/H340A enzyme 
was similar to that of the rat peroxisomal en- 
zyme but was completely insensitive to malonyl- 
CoA and etomoxir. These results indicate that 
the histidine residues His-131 and His-340 are the 
sites responsible for the interaction of these two 
inhibitors, which inhibit COT by interacting with 
the same sites. 
Introduction 
Carnitine octanoyltransferase (COT) facilitates 
the transport of medium-chain fatty acids from 
peroxisomes to mitochondria through the con- 
Fatty Acid Oxidation and Ketone Body Metabolism 
version of shortened fatty acyl-CoAs, formed from 
peroxisomal P-oxidation, into fatty acyl-carnitine 
[1,2]. C O T  might have other roles because it 
shows activity in other organelles such as micro- 
somes, nuclei and mitochondria [3,4]. 
In the course of our research, natural trans- 
splicing was observed in rat COT pre-mRNA 
species [S] in vivo; this was also reproduced in 
vitro. This mechanism produces two different 
transcripts in which exons 2 and 3 are repeated. 
Western blot analysis of peroxisomal proteins 
revealed two translated proteins with molecular 
masses that might correspond to the cis-spliced 
mRNA as well as the higher-molecular-mass 
trans-spliced RNA species. These results raised 
the questions of whether the occurrence of the 
three mRNA products is regulated by different 
metabolic conditions, or depends on sex, or is 
present in one or several tissues, or whether a 
signal in exon 2 has a role. In the first part of this 
paper we attempt to answer these questions. 
Peroxisomal rat C O T  is inhibited by malonyl- 
CoA, as is carnitine palmitoyltransferase I (CPT 
I). Moreover, CPT I and COT are also inhibited 
by 2-[6-(4-chlorophenoxy)hexyl]oxirane carboxy- 
lic acid (etomoxir) [6-81. In contrast, etomoxir 
does not inhibit CPT 11. Binding studies suggest 
that etomoxir, like malonyl-CoA, interacts with 
C P T  I at two sites [9] and the inhibitory properties 
of etomoxir resemble those of malonyl-CoA except 
for the irreversibility of the reaction. Because the 
described interaction between malonyl-CoA and 
C P T  I involves two histidine sites, one that affects 
the acyl-CoA-binding domain [lo] and one that 
behaves as an allosteric component [ll-131, we 
explored the histidine residues involved in this 
binding in COT. 
Thus we analysed the inhibitory kinetics of 
malonyl-CoA in a yeast-expressed C O T  and com- 
pared these data with those for etomoxir. We 
identified His-131 and His-340 as the residues 
involved in the response to both malonyl-CoA 
[14] and etomoxir [15] because their mutation 
abolishes inhibition in both cases. 
Results and discussion 
Molecular basis of rat COT trans-splicing 
Rat produces three different C O T  transcripts with 
the following compositions : exonlLexon2-exon3, 
etc., exonl-exon2-exon2Lexon3, etc., and exonl- 
exon2-exon3-exon2-exon3, etc [S]. We therefore 
attempted to determine the molecular basis for 
trans-splicing in the rat COT. 
We examined whether the trans-splicing ob- 
served for rat COT could be sex-dependent and 
tissue-dependent or produced as a result of meta- 
bolic alteration. Both male and female adult rats 
gave three mature transcripts of the COT gene 
(Figure 1). Reverse-transcriptase-mediated PCR 
amplification of transcripts from different rat 
tissues such as liver, intestine, testis, kidney, heart 
and brown adipose tissue also gave the three- 
transcript pattern, as well as rats fed with a fat diet 
or a diet supplemented with diethyl hexyl phthal- 
ate (results not shown). The  variability in the 
relative proportions of the three transcripts had 
been observed previously [S]. All these results 
suggest that trans-splicing in rat C O T  depends on 
the gene sequence rather than on tissue expression, 
diet or treatment with diethyl hexyl phthalate. 
In rat C O T  exon 2, at least one purine-rich 
sequence was identified at position 147 
(GAAGAAG), which is similar to exonic splicing 
enhancer (ESE) sequences previously described 
[ 16-1 81. We attempted to assess whether the 
change of GAAGAAG to AAAAAAA, which has 
been described as a factor that abolishes trans- 
splicing, is responsible for the decrease in 
trans-splicing in the rat [19]. T o  this end, trans- 
Figure I 
Reverse-transcriptase-mediated PCR amplification of 
the mRNA species of COT of rat males and females 
Representative data ofthe RT-PCR reaction oftotal liver RNA [5] 
from six male and six female rats. The primers used were 5’- 
TmCrrACTGTGACTATACCATGG-3’ (exon 2 ,  forward) 
and 5’-GGTTCATGTCTAGAGGAG-3’ (exon 5, reverse). The 
bands were sequenced and corresponded to cis-splicing 523 bp 
and trans-splicing 659 and 784 bp. Lane M, molecular mass 
markers. 
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splicing was performed in vitro with donor and 
acceptor constructs of rat exon 2 and neighbouring 
introns in which the ESE sequence, GAAGAAG, 
was mutated to AAAAAAA, to examine the effect 
of this mutation on trans-splicing. 
Figure 2 shows that the combination of donor 
construct G and acceptor construct F in vitro 
inhibits trans-splicing (60 %) in comparison with 
the trans-splicing of non-mutated constructs (do- 
nor construct A and acceptor B) (see lanes 17-20 
and 3-6). Figure 2 also shows that the combination 
of donor A and acceptor F (lanes 7-10) produced 
similar inhibition of the trans-splicing in vitro 
(60 yo) to that of the combination G x F. This 
inhibition was not observed with the combination 
G x B, in which a small decrease (1 6 % in all lanes) 
was observed (compare lanes 13-16 with 3-6), 
indicating that the mutation has a greater effect on 
the acceptor function. 
We conclude that we have found an ESE box 
(GAAGAAG) in rat C O T  exon 2 that could be 
Figure 2 
Mutation in the ESE box of rat exon 2 from 
GAAGAAG to AAAAAAA inhibits trans-splicing 
in vitro 
Trans-splicing assays in vim [5] contained nuclear extracts and 
0.9 ng ( I 6 fmol) of 32P-radiolabelled A pre-mRNA (lanes I - 10) 
or 32P-radiolabelled G pre-mRNA (lanes 11-20) and increasing 
amounts r25.50, I00 and 200 ng (280,555, I I08 and 2220 fmol)] 
of either acceptor B (lanes 3 4  or 13- 16) or acceptor F (lanes 
7- I0 or 17-20), The letters AAAAAAA in the G donor and F 
acceptor indicate that the wild-type ESE box GAAGAAG was 
mutated to  AAAAAAA. Lane 2 I ,  molecular mass markers. Lanes 
I and I I corresponded to  incubations in the absence of any 
acceptor but in the presence of ATP. Lanes 2 and 12 were 
controls without ATP but with 200 ng of construct B. Branch 
points are shown by circles in the acceptor constructs. 
responsible for the natural trans-splicing in rat, by 
generating three transcripts that encode two 
proteins in vivo. 
Effect of malonyl-CoA and etomoxir on 
COT activity 
Peroxisomal C O T  is inhibited reversibly by 
malonyl-CoA and irreversibly by etomoxir. T o  
determine which of the histidine residues of C O T  
were potentially responsible for the inhibitory 
action of malonyl-CoA and etomoxir, we 
examined all the histidine residues common to a 
number of carnitine acyltransferases. Only two 
residues, present in the malonyl-CoA- and 
etomoxir-inhibitable enzymes and absent from 
non-inhibitable carnitine acyltransferases, were 
considered as candidates for inhibition by 
malonyl-CoA and etomoxir: His-131 and His-340 
of rat COT. We therefore decided to mutate these 
two residues. Our approach was to express the 
wild-type and mutated enzymes in yeast and to 
evaluate the C O T  activity and the inhibitory effect 
of malonyl-CoA and etomoxir. 
The  pYES2 plasmids containing the wild- 
type and the double mutant H131AIH340A of 
C O T  were expressed in Saccharomyces cerevisiae. 
When the wild-type C O T  was expressed, we 
obtained a preparation of C O T  protein with a 
specific activity of 205 nmol/min per mg of pro- 
tein, i.e. 9-fold that of rat liver peroxisomes. 
Mutations of both His-131 and His-340 in 
yeast-expressed C O T  produced small changes 
in the K ,  and V,,, for carnitine and decanoyl-CoA 
as substrates. The  K ,  values for carnitine were 
172 p M  (wild type) and 106 p M  (double mutant). 
The  K ,  values for decanoyl-CoA were 2 pM (wild 
type) and 13 p M  (double mutant). The  V,,, values 
of the different enzymes varied less for carnitine as 
the varied substrate than for decanoyl-CoA. An 
immunoblot analysis showed that all transformed 
yeast cells expressed a protein with the same 
molecular mass and in roughly the same pro- 
portion per mg of total protein [15]. 
Figure 3 shows the etomoxiryl-CoA- and 
malonyl-CoA-dependent inhibition of yeast-ex- 
pressed wild-type COT. The  absence of endogen- 
ous C O T  from yeast and the observation of C O T  
activity in yeast extracts indicate that yeast is a 
suitable organism in which to study the inhibition 
of C O T  by these inhibitors. In Figure 3 it is also 
observed that yeast-expressed C O T  shows a de- 
crease in sensitivity towards malonyl-CoA and 
etomoxir compared with rat liver peroxisomes. 
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Figure 3 
Effect of malonyl-CoA and etomoxiryl-CoA on the activity of the wild-type 
COT and the double mutant H I3 IAIH340A 
5. cerevisiae cells were transformed with the COT cDNA species forthe wild-type enzyme (0) 
and for the H I3 I NH340A double mutant (m). Yeast extracts were incubated with increasing 
concentrations of malonyl-CoA [ I41 and etomoxiryl-CoA [ 151. The curves corresponding t o  
peroxisomal COT (as controls) are also shown (A). Data are expressed relative to control 
values in the absence of inhibitors ( I  00%) as means ofthree independent measurements; error 
bars show S.D. 
A 
0 
I I I I I I I 1 I 1 1 I 
0 50 100 150 200 0 5 10 15 20 25 30 
Malonyl-CoA (pM) Etomoxiryl-CoA (pM) 
Figure 3 also shows the inhibitory pattern 
of malonyl-CoA and etomoxiryl-CoA on the 
S .  cereoisiue-expressed C O T  double mutant 
H131A/H340A. This mutant variant of the en- 
zyme was not inhibited by malonyl-CoA in the 
range 1-200pM or by etomoxir at any concen- 
tration in the range 1-30 pM. 
It has long been assumed that regulation of 
carnitine acyltransferases by etomoxir and related 
compounds affects only mitochondria1 C P T  I. 
However, Skorin et al. [20] and Lilly et al. [21] 
showed that etomoxir and analogous drugs inhibit 
C O T  and C P T  I with similar intensities in rat 
liver mitochondria and peroxisomes. Our studies 
here show that C O T  is inhibited by etomoxir and 
malonyl-CoA in a concentration-dependent 
manner. 
Studies by A’Bhaird and Ramsay [22] showed 
that malonyl-CoA binds to rat peroxisomal C O T  
at two separate sites. At one of these sites, which is 
thought to be within the catalytic domain, 
malonyl-CoA competes with the substrate, 
decanoyl-CoA, in a similar way to the inhibition 
produced by several CoA esters such as glutaryl- 
CoA, 3-hydroxy-3-methylglutaryl-CoA and 
methylmalonyl-CoA. In addition, there is 
another, more specific site, to which malonyl-CoA 
binds as an allosteric effector but to which the 
other CoA-related products do not bind. Several 
reports had suggested that the interaction of 
malonyl-CoA with carnitine acyltransferases is 
exerted through histidine residues [23,24] ; since 
then, various authors have attempted to identify 
the histidine residues responsible for the inhi- 
bition. 
The  double mutant H131A/H340A showed 
no inhibition at low or high concentrations of 
either malonyl-CoA or etomoxir, despite the fact 
that the enzyme was fully active. This is the best 
demonstration that these two histidine residues 
are responsible for the inhibition by these in- 
hibitors. The  coincidence of lack of inhibition by 
malonyl-CoA and etomoxir in the double mutant 
H131A/H340A is additional evidence that 
malonyl-CoA and etomoxir-CoA bind to C O T  at 
the same site, as was proposed for C P T  I [9]. 
These results can serve as a model to study 
the effect of specific mutations in amino acid 
residues that bind malonyl-CoA and etomoxir in 
other carnitine acyltransferases and might facili- 
tate the development of other drugs that interfere 
with the metabolism of fatty acids in different 
tissues. 
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Abstract 
Rumenic acid (cis-9, trans-1 l-C18:z) represents 
approx. 80 yo of conjugated linoleic acid (CLA) in 
dairy products. CLA has been shown to exert 
beneficial effects on health, but little work has 
been devoted to the ability to oxidize CLA isomers 
and the role of these isomers in the modulation of 
p-oxidation flux. In the present study, respiration 
on rumenic acid was compared with that on 
linoleic acid (cis-9, cis-l2-C,,:,) with the use of rat 
liver mitochondria. In state-3, respiration was 
decreased by half with rumenic acid in comparison 
with linoleic acid. In the uncoupled state, res- 
piration on CLA remained 30 yo lower. The  lower 
ability to oxidize CLA was investigated through 
characterization of the enzymic steps. Rumenic 
acid was 33 yo less activated by acyl-CoA synthase 
than was linoleic acid. However, after such ac- 
tivation, the transfer of both acyl moieties to 
carnitine by carnitine acyltransferase I (CAT I) 
was of the same order. Moreover, CAT I1 activity 
was comparable with either isomer. After prior 
incubation with rumenic acid, oxidation of octa- 
noic acid by re-isolated mitochondria was un- 
impaired, but that of palmitoleic acid was impaired 
unless linoleic acid was used in the prior 
incubation. The  slower respiration on cis-9, 
trans-1 l-C18:2 is suggested to arise from lower 
carnitine-acylcarnitine translocase activity to- 
wards the acylcarnitine form, causing an upstream 
increase in the corresponding acyl-CoA. 
Introduction 
Fatty acid classification of rumenic acid 
Key words: p-oxidation, camitine system, conjugated linoleic acid, Rumenic acid is the predominant form of a group 
mitochondria. of positional and geometrical isomers of octa- - 
Abbreviations used: ACS, acyl-CoA synthase; CAT, camitine 
acyttransferase; CLA. conjugated linoleic acid; DTT, dithiothreitol; 
FCCP, carbonyl cyanide p-trifluorornethoxyphenylhydrazone. 
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